Zevra Therapeutics (ZVRA) Competitors

Zevra Therapeutics (NASDAQ:ZVRA) and Galapagos (NASDAQ:GLPG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Which has stronger valuation & earnings, ZVRA or GLPG?

Galapagos has higher revenue and earnings than Zevra Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$24.49M	18.48	-$46.05M	-$1.97	-4.30
Galapagos	$260.09M	6.87	$229.12M	N/A	N/A

Does the MarketBeat Community prefer ZVRA or GLPG?

Galapagos received 437 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 64.10% of users gave Galapagos an outperform vote.

Company	Underperform	Outperform
Zevra Therapeutics	Outperform Votes 29 100.00%	Underperform Votes No Votes
Galapagos	Outperform Votes 466 64.10%	Underperform Votes 261 35.90%

Do analysts recommend ZVRA or GLPG?

Zevra Therapeutics presently has a consensus price target of $21.00, indicating a potential upside of 147.64%. Galapagos has a consensus price target of $30.75, indicating a potential upside of 13.38%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Zevra Therapeutics is more favorable than Galapagos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
Galapagos	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Which has more risk & volatility, ZVRA or GLPG?

Zevra Therapeutics has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.

Do institutionals & insiders hold more shares of ZVRA or GLPG?

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 32.5% of Galapagos shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 2.9% of Galapagos shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Is ZVRA or GLPG more profitable?

Galapagos has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -342.63%. Galapagos' return on equity of 0.00% beat Zevra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	-342.63%	-159.54%	-51.50%
Galapagos	N/A	N/A	N/A

Does the media prefer ZVRA or GLPG?

In the previous week, Galapagos had 7 more articles in the media than Zevra Therapeutics. MarketBeat recorded 9 mentions for Galapagos and 2 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 1.39 beat Galapagos' score of 0.56 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galapagos	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zevra Therapeutics beats Galapagos on 9 of the 17 factors compared between the two stocks.